---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Heterogeneity of treatment effect"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Heterogeneity of treatment effect. Topics: RAPIDe-3 subgroups: participants with at least one study drug-treated attack; RAPIDe-3 subgroups: hereditary angioedema with normal C1 inhibitor; RAPIDe-3 limitations bearing on subgroup interpretation; RAPIDe-3 regional subgroups: North America and Europe/Rest of World, all participants with treated attacks; 7 further topics. 11 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### RAPIDe-3 subgroups: participants with at least one study drug-treated attack

> “Sensitivity and subgroup analyses employed an expanded analysis set including all participants who treated at least one attack with study drug”
> “Of the 113 participants who treated at least one attack, 26 (23%) were receiving long-term prophylaxis at enrolment and during the study.”
> “Outcomes were consistent across subgroups defined by age, hereditary angioedema types, whether concomitant long-term prophylaxis was used or not, and attack location and severity”
> “Results were consistent across clinically relevant subgroups defined according to age, geographical location, hereditary angioedema type, concomitant long-term prophylaxis, and attack severities and locations (including non-severe laryngeal).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.3-2"></a>

### RAPIDe-3 subgroups: hereditary angioedema with normal C1 inhibitor

> “In the two participants with hereditary angioedema with normal C1 inhibitor who each had one deucrictibant-treated attack, the time to onset of symptom relief was 1·53 h and 0·84 h, respectively.”
> “Results in the two participants with hereditary angioedema with normal C1 inhibitor with a variant in the plasminogen gene who each had one deucrictibant-treated attack demonstrated a promising response to deucrictibant treatment, but the small dataset and absence of placebo control prevent further speculation on these findings.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.3-3"></a>

### RAPIDe-3 limitations bearing on subgroup interpretation

> “Limitations of this trial include the lack of attack stratification according to location and severity due to the rarity of the disease and the unpredictable nature of attack characteristics. Therefore, a larger proportion of severe attacks was observed in the placebo group. Additionally, only two unpaired attacks for participants with hereditary angioedema with normal C1 inhibitor were recorded. Lastly, severe laryngeal attacks were not included, which is consistent with other placebo-controlled studies of on-demand hereditary angioedema therapies.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.3-4"></a>

### RAPIDe-3 regional subgroups: North America and Europe/Rest of World, all participants with treated attacks

> “subgroup analysis included all participants with treated attacks”
> “In this subgroup analysis, orally administered deucrictibant IR capsule provided faster onset of symptom relief, reduction in attack severity, and complete resolution in both the NA and EU/RoW subgroups compared with placebo.”
> “Data were consistent across geographical locations and with the overall study population.”
> “Deucrictibant IR showed consistent efficacy in treating HAE attacks, regardless of HAE subtypes, age group, LTP use, and attack severity and locations”

Source: [Riedl et al. (2026b)](https://ir.pharvaris.com/static-files/2e62f03b-fbb8-4376-9151-f74c41dd8c0f)

<a id="topic-2.2.2.3-5"></a>

### RAPIDe-3 regional subgroups: median times to onset of symptom relief, reduction in attack severity, and complete resolution

| Outcome and region | Deucrictibant IR | Placebo |
| --- | --- | --- |
| Onset of symptom relief, North America | “1.20 hours (95% CI: 0.84, 1.84)” | “6.55 hours (95% CI: 1.88, >12)” |
| Onset of symptom relief, Europe/Rest of World | “1.28 hours (95% CI: 1.04, 1.41)” | “>12 hours (95% CI: 5.74, >12)” |
| Reduction in attack severity, North America | “2.43 hours (95% CI: 1.03, 5.12)” | “>12 hours (95% CI: 2.65, >12)” |
| Reduction in attack severity, Europe/Rest of World | “2.53 hours (95% CI: 1.70, 2.98)” | “>12 hours (95% CI: 12.10, >12)” |
| Complete symptom resolution, North America | “11.61 hours (95% CI: 2.94, 26.14)” | “>48 hours (95% CI: 17.21, >48)” |
| Complete symptom resolution, Europe/Rest of World | “12.04 hours (95% CI: 8.64, 21.79)” | “>48 hours (95% CI: >48, >48)” |

Source: [Riedl et al. (2026b)](https://ir.pharvaris.com/static-files/2e62f03b-fbb8-4376-9151-f74c41dd8c0f)

<a id="topic-2.2.2.3-6"></a>

### RAPIDe-1 attack location: cutaneous and abdominal attacks

> “For attacks with cutaneous or abdominal manifestations, or both, shorter times to symptom relief and resolution were consistently observed with deucrictibant compared with placebo (appendix pp 13–14).”
> “A higher proportion of attacks primarily occurring in the abdominal area were treated with deucrictibant 10 mg than with other doses or placebo (appendix p 11).”
> “Limitations of the RAPIDe-1 trial include the absence of randomisation of attacks according to location and severity.”
> “Attacks presenting with vomiting or affecting the internal head or neck, including laryngeal attacks, before treatment were excluded from qualification and reoccurrence of attack symptoms following treatment was not evaluated as a predefined endpoint.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.2.2.3-7"></a>

### Sebetralstat pooled phase 2 and 3 trials: subgroups by location, severity, age, sex, region, and regimen

> “In the subgroup analysis, results favoring sebetralstat versus placebo were generally consistent when analyzed by pooled primary HAE attack location (mucosal, abdominal only, or subcutaneous), baseline attack severity, age, sex, geographic region, and treatment regimen (Fig. 3). Of note, HAE attacks with a baseline severity of “Severe” or “Very Severe” more strongly favored sebetralstat over placebo in terms of time to beginning of symptom relief compared with attacks with a baseline severity of “Mild” or “Moderate”, although results should be interpreted with caution due to the wide confidence intervals.”
> “For HAE attacks rated “Severe” or “Very Severe” at baseline, conventional medication was used for 2 of 14 attacks (14.3%) treated with sebetralstat 300 mg, 3 of 20 attacks (15.0%) treated with sebetralstat 600 mg, and 6 of 14 attacks (42.9%) treated with placebo.”
> “Subgroup analyses are exploratory in nature and not adjusted for multiplicity.”

Source: [Aygören-Pürsün et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273462/)

<a id="topic-2.2.2.3-8"></a>

### Sebetralstat open-label extension: attacks during long-term prophylaxis by severity, location, and age

> “In subgroup analyses by attack severity at the time of sebetralstat administration, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 1.8 (1.0-7.0) hours, 1.3 (0.8-3.5) hours, and 1.3 (0.5-1.8) hours for mild, moderate, and severe/very severe attacks, respectively”
> “Subgroup analyses by attack location showed median (IQR) times to beginning of symptom relief in participants receiving any LTP agent of 1.3 (0.7-2.2) hours, 1.4 (0.9-4.1) hours, 1.0 (0.5-2.2), and 1.7 (1.2-6.0) hours for attacks with mucosal involvement, attacks with laryngeal involvement, attacks limited to the abdomen, and attacks limited to subcutaneous tissues, respectively”
> “In subgroup analyses by age, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 0.7 (0.3-1.4) hours and 1.7 (1.1-5.5) hours for participants aged <18 years (n = 5) and participants aged ≥18 years (n = 30), respectively”
> “Furthermore, the study was not designed or powered to evaluate differences in the effectiveness of sebetralstat by the specific LTP agent received or differences between subgroups; these data are reported to offer a preliminary clinical overview.”

Source: [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

<a id="topic-2.2.2.3-9"></a>

### Icatibant: time to treatment, attack location, and severity in the Icatibant Outcome Survey

> “Attack duration was significantly shorter in patients treated <1 hour of attack onset compared with those treated ≥1 hour (6.1 hours versus 16.8 hours [p<0.001]).”
> “Self-administrators were more likely to treat early and experience shorter attacks than those treated by a healthcare professional.”
> “Both abdominal and cutaneous attacks were found to be of shorter total duration when treated early. Additionally, early treatment resulted in significant reductions in attack duration regardless of attack severity (Tables 4 and 5).”

Source: [Maurer et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563637/)

<a id="topic-2.2.2.3-10"></a>

### Ecallantide: response by time to treatment in the EDEMA trials

> “Change from baseline in MSCS score and TOS at 4 hours revealed significantly better response to ecallantide versus placebo for patients treated >2-4 (n = 46; p = 0.002; p = 0.003) or >4-6 (n = 47; p = 0.044; p = 0.043) hours after symptom onset. Fewer patients were treated within 2 hours of symptom onset; for these patients (n = 10; p = 0.752; p = 0.422) treatment did not achieve statistical significance.”

Source: [Banta et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21781409/)

<a id="topic-2.2.2.3-11"></a>

### Icatibant and plasma-derived C1 inhibitor: attack site and time to treatment in a prospective cohort

> “Attack severity and attack site were not found to be associated with different remission rates, with the only exception for laryngeal attacks (HR 1.44, 95% CI 1.07 to 1.95).”
> “In addition, shorter time to treatment was associated with a small (2%) but significant positive effect on remission rates”

Source: [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
